1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSotyktu (deucravacitinib) RFP#1 - 2026 is sponsored by Bristol Myers Squibb Foundation. A request for proposals focusing on Sotyktu (deucravacitinib), with a pre-concept submission period from May 4 to June 25, 2026.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Areas of interest & competitive research grants - Bristol Myers Squibb Areas of interest (AOI) & competitive research grants We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available.
We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
Therapeutic Area and / or Compound Pre-Concept Submission Period Sotyktu (deucravacitinib) RFP#1 - 2026 Admilparant (LPA1) RFP#1 - 2026 Select Your Therapeutic Area At this current time, there are no active Requests for Proposals that are open for submission. Please check the table above for the most up-to-date information on recent and upcoming open submission windows.
Previews of Areas of Interest may be available below for your reference. We are unable to retrieve active requests for proposals (RFPs) due to technical difficulties. Please check back in a few hours.
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS. com. This is part of the normal process.
If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here .
If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
According to the current listing, eligibility includes: Organizations involved in healthcare and scientific research. Confirm the full requirements in the official notice before applying.
The published deadline was June 25, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Sotyktu (deucravacitinib) RFP#1 - 2026 is funded by Bristol Myers Squibb Foundation. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Sickle Cell Disease program (part of Pediatric Cancers and Blood Disorders focus area) is sponsored by Bristol Myers Squibb Foundation. The BMS Foundation, in partnership with Baylor College of Medicine Global Health and Texas Children's Global HOPE Program, supports initiatives to transform pediatric care for sickle cell disease (SCD) in sub-Saharan Africa. This includes building local healthcare capacity and integrating SCD interventions into primary health services.
Bristol Myers Squibb Health Equity Initiatives is a grant from the Bristol Myers Squibb Foundation that funds programs working to remove barriers to quality care for medically underserved and diverse patient populations. Grants ranging from $50,000 to $250,000 support disease awareness and education, health equity initiatives, and other programs aligned with BMS's therapeutic areas of interest including oncology, hematology, immunology, and cardiovascular disease. The foundation accepts applications throughout the year and prioritizes initiatives that improve access to care and advance health equity for all. Eligible applicants are U.S.-based 501(c)(3) nonprofit organizations or academic institutions. International funding opportunities may differ.